New model, new drugs, and a “remarkable” response in adrenal cancer

Two University of Colorado Cancer Center studies presented at ENDO 2018 use new models to identify genetic targets and test promising treatments in adrenal cancer. One patient was treated with the immunotherapy pembrolizumab and now more than a year after starting treatment remains on the drug with 77 percent tumor reduction and no new metastases.

read more

Mental Health and Cancer

“Cancer doesn’t just affect you physically,” says Elissa Kolva, PhD, University of Colorado Cancer Center researcher. “It can affect every aspect of your life including your role in your family, your relationships, your work life, and even your identity.”

read more

Expensive new cancer therapy may be cost effective

Researchers from the University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, selected to estimate the cost-effectiveness of the newly approved CAR-T therapies, have found the clinical benefit may justify the expensive price. The treatments...

read more